A meta-analysis comparing an LH-RH analogue alone with an LH-RH analogue plus TAM in premenopausal women with advanced breast cancer showed that the ORR was 29.7 and 38.8%, the median PFS was 5.4 and 8.7 months, and the median OS was 2.5 and 2.9 years, respectively. The gene discussed is GNRH1; the disease is breast carcinoma.